The maximum approved dose of donepezil is 23 mg per day, delivered as a sustained-release tablet designed for people with moderate to severe Alzheimer’s disease. This sits above the two immediate-release strengths most patients encounter: the 5 mg starting dose and the 10 mg maintenance dose that has been the standard ceiling for mild to moderate disease for decades. The 23 mg formulation was approved in 2010 after a large trial showed a modest cognitive edge over 10 mg, but the story of what “maximum” means in practice is more complicated than a single number suggests, because tolerability, genetics, body weight, and the type of dementia being treated all shape how much donepezil a given person can handle.
How the Three Approved Doses Fit Together
Most people start donepezil at 5 mg once daily. After four to six weeks, if the drug is tolerated, the dose moves up to 10 mg. That two-step ladder was the only option for years and remains the standard path for mild to moderate Alzheimer’s disease. The 23 mg sustained-release tablet was developed specifically for patients who have already been stable on 10 mg for at least three months and whose disease has progressed to a moderate or severe stage. It is not a simple doubling of the 10 mg pill. The sustained-release formulation dissolves more slowly, producing a flatter drug-level curve over the day rather than a sharp peak and trough.
A pharmacokinetic analysis found that the plasma concentrations produced by the 23 mg sustained-release tablet can actually be approximated by giving the conventional immediate-release formulation as either 10 mg twice daily or 20 mg once daily.1Journal of the American Medical Directors Association. Pharmacovigilance Donepezil Dosing Strategies: Pharmacokinetic Considerations That detail matters less for everyday prescribing, since the sustained-release product is the only version approved at that dose, but it illustrates that the 23 mg tablet is not delivering a dramatically higher drug exposure than what could theoretically be achieved with the older pills. Its advantage is a smoother absorption profile, which helps blunt the gastrointestinal side effects that come with higher doses.
What the Maximum Dose Actually Achieves
The pivotal trial behind the 23 mg approval was a 24-week, double-blind study comparing patients who stayed on 10 mg daily against those who switched to 23 mg. Both groups had moderate to severe Alzheimer’s disease. By the end of the trial, the 23 mg group scored about 2.2 points higher on the Severe Impairment Battery, a cognitive test scaled from 0 to 100, compared with the 10 mg group.2PubMed Central. Effectiveness and Tolerability of High-Dose (23 mg/d) Versus Standard-Dose (10 mg/d) Donepezil in Moderate to Severe Alzheimer’s Disease: A 24-Week, Randomized, Double-Blind Study That difference was statistically significant, but clinically it is small. On a 100-point scale, two points might not translate into noticeable day-to-day improvement for many families.
A subgroup analysis of the same trial looked at whether adding memantine to the mix changed the picture. The cognitive benefit on the Severe Impairment Battery held up regardless of whether patients were also taking memantine. However, the higher dose showed no advantage on global function ratings, the Mini-Mental State Examination, or measures of daily living activities in either subgroup.3PubMed. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer’s disease: a subgroup analysis in patients already taking or not taking concomitant memantine In other words, the maximum dose helps on one specific cognitive measure, but the gains do not consistently show up across every way of measuring how a patient is doing. This is a genuine limitation that clinicians weigh when deciding whether stepping up from 10 mg is worth the added side effects.
Side Effects Get Worse at Higher Doses
Donepezil’s side-effect profile at any dose is dominated by the gut. The drug boosts acetylcholine throughout the body, not just in the brain, and the digestive tract is rich in acetylcholine receptors. At 23 mg, the most common problems in clinical trials were nausea (about 12% of patients), vomiting (about 9%), and diarrhea (about 8%), compared with roughly 3%, 2.5%, and 5% in those staying on 10 mg.4PubMed Central. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease The vomiting rate nearly quadrupled. These gastrointestinal events were also the main reason patients dropped out of the higher-dose group: about 3% quit because of vomiting alone, compared with under half a percent on 10 mg.
There is a silver lining in the timing. Adverse events cluster in the first month after the dose increase and become relatively uncommon after that.5PubMed. Higher-dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer’s disease A separate trial tested whether adding an intermediate titration step, rather than jumping straight from 10 mg to 23 mg, could ease the transition. The titration groups experienced significantly fewer cases of nausea compared with those who switched directly.6PubMed Central. Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg So how a patient reaches the maximum dose matters almost as much as whether they get there.
Cardiovascular Effects Worth Knowing About
Because acetylcholine slows the heart, donepezil can lower heart rate. In a study tracking cardiovascular markers over eight months, the average resting heart rate dropped from about 66 beats per minute at baseline to around 61 or 62 beats per minute during treatment. One patient developed syncope from a drop in blood pressure on standing, though no cases of bradycardia-induced fainting were recorded.7PubMed. Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer’s disease A four- or five-beat-per-minute decrease sounds trivial, but in a frail older adult who already has a slow resting rate or takes a beta-blocker, the cumulative effect can push the heart rate low enough to cause dizziness or falls. This is one reason prescribers check heart rate and rhythm before and during treatment, especially at higher doses.
Genetics and Drug Interactions Can Raise Your Effective Dose
Donepezil is broken down in the liver mainly by two enzyme families. Genetic variation in one of those enzymes, CYP2D6, has a meaningful effect on how much drug accumulates in the blood. A population pharmacokinetics study found that people who are “poor metabolizers” of CYP2D6 clear donepezil about 32% more slowly than typical metabolizers, while “ultrarapid metabolizers” eliminate it roughly 67% faster.8PubMed Central. Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance In practical terms, a poor metabolizer taking 10 mg may carry drug levels closer to what an average person would see on a higher dose, while an ultrarapid metabolizer might barely reach therapeutic levels.
It is not just genetics. Other medications can slow donepezil’s clearance too. Patients taking drugs that inhibit CYP2D6 or a transporter protein called P-glycoprotein had plasma donepezil concentrations that were significantly higher than those in patients not on such medications.9PubMed. Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer’s disease Common culprits include certain antidepressants, antifungals, and heart-rhythm drugs. This matters because a patient already on 23 mg who then starts one of these interacting medications can effectively overshoot the intended exposure without anyone changing the donepezil prescription.
Body Weight Affects Tolerability
Older adults with lower body mass index appear to be hit harder by side effects from the sustained-release formulation. In a study comparing tolerability by BMI group, patients with lower BMI reported treatment-emergent adverse events at a rate of about 79%, versus about 58% in the higher BMI group. A survival analysis confirmed that the lower BMI group had a significantly higher hazard of experiencing adverse events.10Journal of Clinical Psychopharmacology. Adverse Events With Sustained-Release Donepezil in Alzheimer Disease The explanation is straightforward: a lighter person reaches higher drug concentrations from the same fixed dose. For underweight patients, this means the maximum dose carries proportionally greater risk, and some clinicians opt to stay at 10 mg rather than push to 23 mg.
Combining Donepezil With Memantine
Many patients with moderate to severe Alzheimer’s disease take donepezil alongside memantine, a drug that works through a different brain pathway. A recent trial compared low-dose donepezil (5 mg) plus memantine against high-dose donepezil (10 mg) plus memantine over 24 weeks. The two groups showed similar improvements in cognition, behavior, and daily function. However, the high-dose group had significantly worse sleep quality scores and a higher rate of adverse reactions, about 28% versus 11% in the low-dose group. The low-dose combination also produced better quality-of-life ratings.11PubMed. Combined Effects of Donepezil and Memantine on Behavioral and Psychological Symptoms, Cognitive Function, and Daily Living Abilities in Patients With Alzheimer’s Disease This is an important finding because it suggests that when memantine is already on board, pushing donepezil higher may add side effects without meaningful extra benefit. It reinforces that the maximum dose is not automatically the best dose for every patient.
What Happens in an Overdose
Accidental overdoses with donepezil do occur, usually through medication errors in assisted-living settings or confused self-dosing. A published case report described a patient who mistakenly received ten times her intended dose. She arrived at the emergency department with nausea, vomiting, and a heart rate stuck in the 40s. Treatment required repeated boluses of atropine, a drug that counteracts acetylcholine’s effect on the heart, totaling 3 mg over 18 hours. Each dose would lift the heart rate above 60 beats per minute for an hour or two before the bradycardia returned.12PubMed. Donepezil overdose: a tenfold dosing error The patient recovered, but the case illustrates why donepezil overdose is a medical emergency: the sustained heart-rate depression can become dangerous quickly, especially in an elderly person with existing cardiac vulnerability. Because donepezil has a long half-life of roughly 70 hours, the effects of an overdose can persist for days, far outlasting a single dose of atropine.
Sleep Disruption and Nightmares
Donepezil is known to alter sleep architecture, and this effect scales with dose. A systematic review found that nightmares can develop during treatment, particularly when the drug is taken in the evening. The relationship with sleep is complicated: while donepezil can trigger vivid or disturbing dreams in people with mild cognitive impairment or Alzheimer’s disease, the same drug has paradoxically been studied as a treatment for nightmares in post-traumatic stress disorder and other psychiatric conditions.13Journal of the Formosan Medical Association. The association of changes of sleep architecture related to donepezil: A systematic review and meta-analysis For patients on the maximum dose who develop sleep problems, the most common practical solution is switching the medication to a morning schedule. If nightmares persist, it becomes a question of whether the cognitive benefit justifies the sleep cost, particularly since poor sleep itself worsens cognitive function in dementia.
The Danger of Stopping Abruptly
One risk that is easy to overlook with donepezil, at any dose, is what happens when it is stopped suddenly. A case report described a patient who had been stable on 10 mg daily for years. Within three days of discontinuation, she developed a fluctuating level of consciousness, possible hallucinations, and greatly intensified dementia symptoms. She was diagnosed with delirium on top of her underlying dementia.14PubMed Central. Withdrawal syndrome after donepezil cessation in a patient with dementia
An open-label study in patients with Lewy body dementia and Parkinson’s disease dementia confirmed the pattern more broadly. Patients who improved on donepezil lost those gains quickly after withdrawal, showing significant cognitive and behavioral decline. Restarting the drug restored the improvements.15PubMed. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia The clinical takeaway is clear: if donepezil needs to be stopped, whether because of side effects, a change in goals of care, or a switch to a different medication, tapering under medical supervision is the safer path. At the 23 mg dose, the abrupt withdrawal concern is at least as relevant, since higher steady-state drug levels mean a steeper drop when the drug is removed.
Donepezil in Lewy Body Dementia
Although the 23 mg dose is approved specifically for Alzheimer’s disease, donepezil at lower doses has a solid evidence base in dementia with Lewy bodies. A randomized, placebo-controlled trial found that both 5 mg and 10 mg daily produced significant improvements in cognition and behavior in these patients, with safety results consistent with the known profile of the drug.16PubMed Central. Donepezil for Dementia with Lewy Bodies: A Randomized, Placebo-Controlled Trial A follow-up open-label extension showed that benefits at 10 mg were sustained for up to a year without new safety concerns.17PubMed Central. Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial The maximum dose used in these trials was 10 mg, and there is no published trial testing 23 mg in Lewy body dementia. So while the drug clearly helps in this population, the approved maximum for Alzheimer’s disease should not be assumed to apply here.
Transdermal Patches and Other Delivery Routes
For patients who cannot tolerate oral donepezil at any dose, a transdermal patch is in development. A 24-week trial compared a 27.5 mg donepezil patch against 5 mg oral tablets in mild to moderate Alzheimer’s disease, testing whether the patch could match the tablet’s efficacy while potentially reducing gastrointestinal exposure.18PubMed. Efficacy and safety of a transdermal donepezil patch in patients with mild-to-moderate Alzheimer’s disease: A 24-week, randomized, multicenter, double-blind, parallel group, non-inferiority study The patch delivers the drug through the skin, bypassing the stomach entirely. While not yet widely available, this route may eventually let patients who are limited by nausea or vomiting access effective drug levels that they could not reach by mouth. It also addresses a practical problem in advanced dementia: patients who struggle to swallow tablets reliably.
How Donepezil Compares With Other Cholinesterase Inhibitors
Donepezil is not the only drug in its class. Rivastigmine and galantamine are the other two cholinesterase inhibitors commonly prescribed for Alzheimer’s disease. One pharmacological difference worth noting is that donepezil and galantamine selectively inhibit acetylcholinesterase, whereas rivastigmine also inhibits a second enzyme called butyrylcholinesterase.19PubMed. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors Whether that dual inhibition translates into a clinical advantage is debated, but it means the drugs are not interchangeable. Rivastigmine already comes as a patch, which is one reason patients intolerant of oral donepezil sometimes switch to rivastigmine rather than waiting for a donepezil patch. Donepezil’s long half-life, around 70 hours, gives it the convenience of once-daily dosing, something the other two drugs do not share. That same long half-life, though, is the reason overdoses and withdrawal syndromes linger for days.